Tenax Therapeutics, Inc. (TENX) earnings
TENX earnings moved a median of -0.87% by the close. Quarterly and annual TENX reports and results, each read against the price at its own news timestamp. Back to the TENX overview →
20 measured TENX earnings events.
Where these TENX earnings landedvs 18 measured TENX earnings reactions
| Middle 50% of TENX earnings reactions | -1.91% to +1.61% |
|---|---|
| Median reaction (to close) | -0.87% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 TENX earnings events with a measured close landed between -1.91% and +1.61%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q TENAX THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | +0.45% | -5.94% | |
| Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | +0.15% | -8.91% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | -1.73% | -2.14% | |
| Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | -1.47% | -0.81% | |
| Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +12.38% | +20.92% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | — | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +2.23% | |
| Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | +2.23% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -0.87% | |
| Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | -0.87% | |
| Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -8.61% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | +0.21% | +1.86% | |
| Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | Press release | -2.80% | -4.81% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | -0.75% | -1.25% | |
| Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update | Press release | -0.75% | -1.25% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -0.55% | |
| Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update | Press release | +4.36% | +0.87% | |
| Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | -0.08% | +1.92% | |
| Form 10-Q TENAX THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | +4.02% | -0.90% |
Keep exploring
More TENX: analyst actions → · SEC filings → · TENX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Xencor, Inc. (XNCR) | 285 | +0.09% | 52% |
| NOVELION THERAPEUTICS INC COMMON SHARES (NVLN) | 283 | 0.00% | 42% |
| GEMPHIRE THERAPEUTICS INC COMMON (GEMP) | 282 | -1.00% | 30% |
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.